Elucida Oncology Announces Abstract Accepted for Poster Presentation at ESMO Congress 2023 Sep 11, 2023
Elucida Oncology Announces First Patient Dosed with ELU001 in Expansion Cohort of its Phase 1/2 Clinical Trial Jul 20, 2023
Elucida Oncology Announces Positive Early Phase 1 Safety Data Along with Preclinical Data for the Treatment of Brain Metastases for ELU001, an Anti-Folate Receptor Alpha C’Dot Drug Conjugate Apr 20, 2023
Elucida Oncology to Present New Clinical and Preclinical Data at the 2023 AACR Annual Meeting Apr 11, 2023
Elucida Oncology to Present Trials in Progress Poster for Phase 1/2 Study of ELU001 in Patients with Advanced, Recurrent, or Refractory Cancers Overexpressing FRα at 2022 American Society of Clinical Oncology Annual Meeting Jun 1, 2022
